MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock from...
$4,040K
Net cash provided by
financing activities
$4,040K
Net decrease in cash
and cash...
$1,810K
Canceled cashflow
$2,230K
Stock-based compensation
$108K
Change in fair value of
derivative warrant...
$40K
Trade and other
payables
$36K
Depreciation expense
$3K
Net cash used in
operating activities
-$2,230K
Canceled cashflow
$187K
Interest income, net
$172K
Net loss
-$2,314K
Canceled cashflow
$172K
Prepaid expenses
$103K
Professional fees
$870K
Salaries and benefits
$751K
Other general and
administrative expenses
$594K
Clinical development
programs
$124K
Stock-based compensation
$109K
Other segment income
-$38K
Back
Back
Cash Flow
source: myfinsight.com
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)